Aflibercept

From Anvita Health Wiki

Contents 1 Indications 2 Contraindications 3 Dosage 4 Adverse-effects 5 Mechanism-of-action 6 Notes 7 More General Terms 8 References

Indications

• wet age-related macular degeneration

Contraindications

• active eye infection
• active ocular inflammation

Dosage

• 2 mg (0.05 mL) every 4 weeks for 3 months, then 2 mg (0.05 mL) every 8 weeks
  

• Solution: 40 mg/mL solution for intravitreal injection in a single-use vial

Adverse-effects

• eye pain
• conjunctival hemorrhage
• vitreous floaters
• cataract
• increased intraocular pressure (may occur within 60 minutes)
• endophthalmitis & retinal detachments may occur following intravitreal injections

Mechanism-of-action

• recombinant fusion protein consisting of portions of human VEGF receptor 1 & VEGF receptor 2 extracellular domains fused to the Fc portion of human IgG1
• acts as a soluble decoy receptor that binds VEGF-A and PlGF

Notes

• in two randomized trials, involving 2400 patients, aflibercept was as effective as ranibizumab ( Lucentis) in improving visual acuity

More General Terms

• enzyme inhibitor
• ophthalmic agent (eyedrops)

References

1. FDA NEWS RELEASE: Nov. 18, 2011 FDA approves Eylea for eye disorder in older people [1]
2. aflibercept (Eylea) prescribing information [2]

aflibercept (Eylea)